63 results
P
advanced colorectal cancer patients
I/C
pharmacological therapies, including systemic chemotherapies, anti-epidermal growth factor receptor therapies and anti-angiogenic agents, treatment effects on surrogate endpoints (TR, PFS) and final outcome (OS)
O
overall survival (OS)
P
brain abscesses
I/C
aspiration, excision, aspiration vs excision
O
mortality, re-operation rate, functional outcome
P
IHCs
I/C
Pegylated interferon (Peg-IFN) treatment, Control group (including nucleos(t)ide analogue (NA) treatment or no treatment)
O
HBsAg clearance rate, conversion rate
P
adults in the European Union
I/C
single-item sedentary behaviour questions within national language versions of most commonly used international physical activity questionnaires, Quility Assessment of Physical Activity Questionnaires checklist
O
reliability, criterion validity, and construct validity
P
individuals with tetraplegia
I/C
respiratory muscle training (RMT)
O
force vital capacity (FVC)
P
professional soccer players with and without macroinjury of the knee joint
I/C
knee osteoarthritis
O
pooled odds ratio for objectively ascertained osteoarthrosis of the knee
P
patients with previous CABG
I/C
coronary artery bypass graft (CABG) markers, with and without radio-opaque markers
O
fluoroscopy time, amount of contrast, and duration of angiography
P
SLE patients
I/C
detection of anti-RibP autoantibodies, other SLE autoantibodies such as anti-Sm and anti-dsDNA
O
prevalence, clinical and serological associations in SLE
P
627 cases, 365 controls
I/C
Eosinophilic esophagitis (EoE)-Custom single-nucleotide polymorphism (SNP) Chip, Meta-analysis with 2 independent EoE genome-wide association studies
O
Identification of replicated association and genome-wide significance at 6 loci: 2p23, 5q22, 10p14, 11q13, and 16p13; identification of 7 additional loci at suggestive significance (P < 10^(-10))
P
CF individuals
I/C
intestinal microbiota, healthy controls
O
reduction in microbial diversity and abundance of some bacterial markers